Finance

Lists
Why is CTNM down 3.98%?
Dive Deeper
CTNM:NASDAQ
Contineum Therapeutics Inc
$ 8.68
-3.98%
(-0.36) 1D
$ 8.68
0.00% (0.00)
After hours
Closed: 11-р сарын 20, 16:00:00 (GMT-5)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
$ 8.87
High
$ 9.11
Low
$ 8.50
Mkt. cap
340.83 сая
Avg. vol.
962.81 мян
Volume
369.21 мян
52-wk high
$ 17.78
52-wk low
$ 6.72
EPS
-$ 1.77
Shares outstanding
35.35 сая
No. of employees
51
Open
$ 8.87
High
$ 9.11
Low
$ 8.50
Mkt. cap
340.83 сая
Avg. vol.
962.81 мян
Volume
369.21 мян
52-wk high
$ 17.78
52-wk low
$ 6.72
EPS
-$ 1.77
Shares outstanding
35.35 сая
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current $ 8.68
$ 30.00 (+245.62%)
Average
$ 22.14 (+155.07%)
Lowest
$ 14.00 (+61.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Hold
Reiterated
$ 17.00
+95.9%
11/18/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$ 21.00
+141.9%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$ 30.00
+245.6%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
$ 14.00
+61.3%
10/14/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$ 28.00
+222.6%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$ 23.00
+165%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$ 22.00
+153.5%
09/16/2026
Last report
2026 оны 11-р сарын 3
Fiscal period
Q3 2026
-$ 0.49 / -$ 0.45
-8.20%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
2026 оны 9-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.00 сая
11.14 сая
11.97 сая
15.26 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.12 сая
5.76 сая
5.45 сая
5.70 сая
Operating expense
17.12 сая
16.90 сая
17.43 сая
20.97 сая
Total operating expenses
17.12 сая
16.90 сая
17.43 сая
20.97 сая
Operating income
-17.12 сая
-16.90 сая
-17.43 сая
-20.97 сая
Other non operating income
-51.00 мян
-57.00 мян
-68.00 мян
-93.00 мян
EBT including unusual items
-15.16 сая
-14.46 сая
-15.15 сая
-18.70 сая
EBT excluding unusual items
-15.16 сая
-14.46 сая
-15.15 сая
-18.70 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.16 сая
-14.46 сая
-15.15 сая
-18.70 сая
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.39
-0.40
-0.49
Interest and investment income
2.01 сая
2.50 сая
2.34 сая
2.36 сая
Interest expense
-
-
-
-
Net interest expenses
2.01 сая
2.50 сая
2.34 сая
2.36 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.03 сая
-16.82 сая
-17.29 сая
-20.88 сая
Gain or loss from assets sale
-
2.00 мян
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google аппс